---
layout: minimal-medicine
title: Vinblastine
---

# Vinblastine
### Generic Name
Vinblastine

### Usage

Vinblastine is a chemotherapy drug, specifically a vinca alkaloid, used to treat various types of cancer.  Its primary use is in the treatment of Hodgkin lymphoma, a cancer of the lymph system.  It's also used for other lymphomas (both lymphocytic and histiocytic), testicular cancer, Kaposi sarcoma (a cancer affecting the skin and blood vessels), and Langerhans cell histiocytosis (a rare disorder affecting the immune system).  Importantly, many of these uses are considered "off-label," meaning they are not officially approved by regulatory bodies for this specific drug but are frequently used by oncologists based on clinical experience and research.  Specific treatment regimens often involve combining vinblastine with other chemotherapy drugs.

### Dosage

Vinblastine is administered intravenously (IV) only; it's fatal if given by any other route.  The Institute for Safe Medication Practices strongly recommends dispensing it in a minibag, not a syringe, to prevent accidental intrathecal (spinal) injection.  Dosage varies greatly depending on the specific cancer being treated, the patient's size (often calculated as body surface area or mg/m²), and the overall treatment plan.  Examples of dosages are provided below, but these should not be interpreted as a recommendation without consultation with an oncologist:

* **Hodgkin Lymphoma:** Dosages range widely depending on the specific regimen (e.g., ABVD, Stanford V, VEPEMB) and stage of disease.  Common doses are around 6 mg/m² given on specific days of a cycle, repeated for several cycles.

* **Other Cancers:**  For non-Hodgkin lymphomas, testicular cancer, Kaposi sarcoma, and Langerhans cell histiocytosis, starting doses might be around 3.7 mg/m² every 7 days, adjusted based on the patient's response and blood cell counts.  Maximum doses generally do not exceed 18.5 mg/m².

* **Pediatric Dosages:**  Dosing in children is also highly individualized and dependent on the type of cancer and the specific treatment protocol.  Dosages are often calculated based on the child's body surface area or weight.

**It's crucial to emphasize that the information above is for illustrative purposes only and should not be used to determine dosing.  A qualified oncologist must determine the correct dosage and treatment plan.**


### Side Effects

Common side effects of vinblastine can include:

* Bone marrow suppression (low blood cell counts – anemia, leukopenia, thrombocytopenia)
* Nausea and vomiting (usually mild)
* Constipation
* Hair loss (alopecia)
* Peripheral neuropathy (numbness or tingling in the hands and feet)
* Headache
* Fatigue
* Mouth sores (stomatitis)

Less common but serious side effects include:

* Severe allergic reactions
* Pulmonary toxicity (lung problems)
* Neurotoxicity (severe nerve damage)
* Cardiac toxicity (heart problems)
* Extravasation (leakage from the vein during IV administration, causing tissue damage)


If any adverse effects occur, especially severe ones, seek immediate medical advice.

### How it Works

Vinblastine works by interfering with cell division.  It binds to tubulin, a protein that forms microtubules, essential components of the cell's internal structure.  By disrupting microtubule formation, vinblastine prevents cells from properly dividing and multiplying, ultimately leading to cell death. This effect is particularly strong on rapidly dividing cancer cells.


### Precautions

* **Contraindications:** Vinblastine is contraindicated in patients with significant granulocytopenia (low white blood cell count), bacterial infections, and pregnancy.

* **Drug Interactions:** Vinblastine can interact with many other medications, including some antibiotics, antifungals, and other chemotherapy drugs.  Always inform your doctor of all medications you are taking.

* **Specific Populations:**  Use in pregnant or breastfeeding women, children, and older adults requires careful monitoring and adjustment of dosage due to increased risk of side effects.

* **Extravasation:**  This is a serious risk during IV administration. If extravasation occurs, the infusion must be stopped immediately, and appropriate measures, often including hyaluronidase injection, should be taken.

* **Hepatic and Renal Impairment:** Dosage adjustments may be necessary for patients with liver or kidney problems.


### FAQs

* **Q: How long will I be on vinblastine?**  A: The duration of treatment depends entirely on your individual situation, the type of cancer, and response to therapy. Your oncologist will determine the treatment schedule.

* **Q:  What should I do if I miss a dose?** A: Contact your doctor or oncology team immediately.  Do not attempt to adjust your dosage on your own.

* **Q:  How should I store vinblastine?** A:  Vinblastine is handled and stored by healthcare professionals.

* **Q: Are there any long-term effects of vinblastine?** A:  Some long-term effects are possible, including peripheral neuropathy and cardiac problems. Your oncologist can discuss the risks.


**Disclaimer:** This information is for general knowledge and does not constitute medical advice.  Always consult a qualified healthcare professional for diagnosis and treatment of any medical condition.  The information provided here is not exhaustive and may not reflect the latest updates.  Always refer to the most current prescribing information for comprehensive details.
